Author Archives: Warren Woessner

Samsung v. Prisua – Fed. Cir. Tries to Eliminate IPR Catch-22

The Fed. Cir. panel decision in Samsung Elec. Amer., Inc. v. Prisua Engineering Corp., Appeal No. 2019-1169, 2019-1260 (Fed. Cir., Feb. 4, 2020) flew under my blogging radar for some time, but since Prisua petitioned for rehearing en banc on … Continue reading

Posted in Inter Partes Review | Tagged | Leave a comment

Advocacy vs. Candor Paves the Road to Inequitable Conduct

In GS Cleantech Corp. v. Adkins Energy LLC, the Fed. Cir. upheld a finding of an on-sale bar to patenting and also found that the main prosecuting attorney committed inequitable conduct by providing false or misleading information to the PTO. … Continue reading

Posted in Federal Circuit | Tagged | Leave a comment

Method of Treatment Efficacy Benchmarks Avoid Inherency Attack

In Galderma Labs. v. Teva Pharm. USA, Inc., Appeal Nos. 2019-2396 and 2020-1213 (Fed. Cir,. January 29, 2020), a Fed. Cir. panel of Judges Moore, O’Malley and Stoll reversed a district court finding that three Galderma patents (US Pat. Nos. … Continue reading

Posted in Anticipation, Inherency | Tagged , | Leave a comment

Trump Signs Economic and Trade Agreement with China

On January 15, 2020, President Trump signed a lengthy “Economic and Trade Agreement Between the Government of the [US] and the Government of [P. R. of China].” Chapter 1 is entitled “Intellectual Property”  that contains Sections on trade secrets, pharmaceuticals, … Continue reading

Posted in Trade Agreements | Tagged , , | Leave a comment